Drug intelligence / Profile preview

Yi Gan Ming Mu (Beijing YouAn Hospital)

Development stage: Unknown
Lead developer: Beijing YouAn Hospital
Administration: Oral

Overview

Yi Gan Ming Mu is a Traditional Chinese Medicine (TCM) oral liquid formulation primarily investigated for the treatment of liver injury associated with chronic hepatitis B. Developed by Beijing Youan Hospital and Capital Medical University, the drug is designed to improve liver function and alleviate clinical symptoms. Its name reflects the TCM principle that the liver's health is manifested in the eyes ("Ming Mu" translates to "brightening the eyes"). Clinical trials, such as ChiCTR-IPC-15006627, have evaluated its safety and efficacy in reducing biochemical markers of liver damage and supporting hepatic recovery in patients with chronic viral infections.

Other names: Yi Gan Ming Mu oral liquidYigan Mingmu oral liquid

Beyond the preview

Go deeper on Yi Gan Ming Mu (Beijing YouAn Hospital).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yi Gan Ming Mu (Beijing YouAn Hospital).

Explore the full profile